Anti-ADX Rabbit Monoclonal Antibody

Western blot analysis of FDX1 using anti-FDX1 antibody (M05441).
Electrophoresis was performed on a 5-20% SDS-PAGE gel at 70V (Stacking gel) / 90V (Resolving gel) for 2-3 hours. The sample well of each lane was loaded with 30 ug of sample under reducing conditions.
Lane 1: human A549 whole cell lysates,
Lane 2: human CACO-2 whole cell lysates,
Lane 3: human SiHa whole cell lysates,
Lane 4: human 293T whole cell lysates,
Lane 5: rat PC-12 whole cell lysates,
Lane 6: rat C6 whole cell lysates.
After electrophoresis, proteins were transferred to a nitrocellulose membrane at 150 mA for 50-90 minutes. Blocked the membrane with 5% non-fat milk/TBS for 1.5 hour at RT. The membrane was incubated with rabbit anti-FDX1 antigen affinity purified monoclonal antibody (Catalog # M05441) at 1:500 overnight at 4°C, then washed with TBS-0.1%Tween 3 times with 5 minutes each and probed with a goat anti-rabbit IgG-HRP secondary antibody at a dilution of 1:1000 for 1.5 hour at RT. The signal is developed using an Enhanced Chemiluminescent detection (ECL) kit (Catalog # EK1002) with Tanon 5200 system. A specific band was detected for FDX1 at approximately 13 kDa. The expected band size for FDX1 is at 19 kDa.

IF analysis of FDX1 using anti-FDX1 antibody (M05441).
FDX1 was detected in an immunocytochemical section of SiHa cells. Enzyme antigen retrieval was performed using IHC enzyme antigen retrieval reagent (AR0022) for 15 mins. The cells were blocked with 10% goat serum. And then incubated at 1:50 rabbit anti-FDX1 Antibody (M05441) overnight at 4°C. Fluoro488 Conjugated Goat Anti-Rabbit IgG (BA1127) was used as secondary antibody at 1:500 dilution and incubated for 30 minutes at 37°C. The section was counterstained with DAPI. Visualize using a fluorescence microscope and filter sets appropriate for the label used.

The expression and the prognosis analysis of immune checkpoints. (A) Expression of immune checkpoint in high and low expression groups of FDX1. (B) Scatter plot of immune checkpoint association with FDX1. (C) Overall survival curve of immune checkpoints in KIRC patients.
Index in PubMed under a CC BY license. PMID: 36755576

Relationship among FDX1 expression, ICB and immune cell infiltration in KIRC. (A) Distribution of immune response scores in high and low expression groups of FDX1. (B) The abundance of immune cell infiltration in FDX1-low group and FDX1-high group in TCGA-KIRC. (C) The Kaplan-Meier curve of Endothelial cells in KIRC. G1 group represented FDX1-high group, G2 group represented FDX1-low group. (D) The abundance of immune cell infiltration in FDX1-low group and FDX1-high group in GSE53757.
Index in PubMed under a CC BY license. PMID: 36755576

The correlation between FDX1 and clinical characteristics in KIRC. (A) The correlation between FDX1 and T stage. (B) The correlation between FDX1 and N stage. (C) The correlation between FDX1 and M stage. (D) The correlation between FDX1 and Age. (E) The correlation between FDX1 and Gender. (F) The correlation between FDX1 and Histologic grade. (G) The correlation between FDX1 and Pathologic stage. (H) The correlation between FDX1 and Laterality. NS, p > .05; *, p < .05; **, p < .01; ***, p < .001.
Index in PubMed under a CC BY license. PMID: 36755576

Correlation between FDX1 and other nine cuproptosis genes. (A) FDX1 and other nine cuproptosis-related molecules co-expression heatmap. (B) 10 cuproptosis-related genes correlation heatmap.
Index in PubMed under a CC BY license. PMID: 36755576

Representative images of FDX1 expression in KIRC tissues and their matched paracancerous tissues. Original magnifications ×100 and 400× (inset panels).
Index in PubMed under a CC BY license. PMID: 36755576

The expression difference of FDX1 in KIRC. (A) Differential expression of FDX1 in paired samples in TCGA-KIRC database. (B) Differential expression of FDX1 in unpaired samples in TCGA-KIRC database. (C) Differential expression of FDX1 in GSE36895. (D) Differential expression of FDX1 in GSE53757. (E) Differential expression of FDX1 between KIRC patients and normal renal tissue by RT-qPCR. (F) Differential expression of FDX1 in TCGA pan cancer. NS, p > .05; *, p < .05; **, p < .01; ***, p < .001.
Index in PubMed under a CC BY license. PMID: 36755576

FDX1, DLAT and CDKN2A cuproptosis-related genes prognostic model. (A) 8,962 potential prognostic molecules of KIRC and 10 cuproptosis-related genes Venn diagram. (B) LASSO variable trajectory diagram. (C) LASSO coefficient screening diagram. (D) The prognostic risk factor graph, red represents high-risk group, blue represents low-risk group. (E) Kaplan-Meier survival curve and time dependent ROC.
Index in PubMed under a CC BY license. PMID: 36755576